Study Group: Oncologists who Treat Multiple Myeloma (US)
Council Members in this Study Group: 74
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
Donald Fleming, MDDivision Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INC
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...
- Eric Jacobsen, MD
Instructor in Medicine
DANA-FARBER CANCER INSTITUTE, INC.Eric Jacobsen, MD, is Medical Oncologist and Hematologist in the Hematology and Oncology Department at the Dana-Farber Cancer Institute in Boston, MA. Dr. Jacobsen is a member of the lymphoma and bone marrow transplant divisions at Dana-Farber Cancer Institute and Instructor in Medicine at Harvard...
Haitham Al-Okk, MDAssistant Clinical Professor - Hematology-Oncology
Mahr Cancer CenterHaitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes in lung, breast, and colorectal...
GLG NewsSM Analyses by this Study Group's Leading Experts (?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
November 14, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
US FDA accepts ChemGenex's Omapro NDA filing to treat CML, grants priority review status | www.pharmabiz.com
Patients with CML have a good prognosis when treated with TKI's An exception is the ones that develope a particular mutation known as T315IOnly SCT seems to be effective in this group of patients and maybe too morbid of therapy for many patients
-
Triple negative Breast Cancer Strategies
October 14, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com
Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as fornon...
-
Farletuzumab (F) helps the ovarian cancer patients that do well, do well?
September 25, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com
F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we...
-
Herceptin for Her2 + gastric cancer, If you can find one
September 25, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com
Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer
-
REGORAFENIB joins a crowd of TKI's for RCC
September 25, 2009
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC
Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com
RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Director
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Physicians who Treat Multiple Myeloma (US) | 183 |
| Oncologists Specializing in Hematologic Malignancies in the U.S. | 422 |
| Oncologists (US) | 2241 |
| Hematologists (US) | 994 |
| Oncologists who Treat Hematologic Malignancies (US) | 855 |
| Multiple Myeloma Physicians | 211 |
| Oncologists who Treat Leukemia (US) | 202 |